Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Accounts Payables (2021 - 2025)

Historic Accounts Payables for Krystal Biotech (KRYS) over the last 5 years, with Q4 2025 value amounting to $39.8 million.

  • Krystal Biotech's Accounts Payables fell 3261.12% to $39.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $39.8 million, marking a year-over-year decrease of 3261.12%. This contributed to the annual value of $39.8 million for FY2025, which is 3261.12% down from last year.
  • Krystal Biotech's Accounts Payables amounted to $39.8 million in Q4 2025, which was down 3261.12% from $31.7 million recorded in Q3 2025.
  • In the past 5 years, Krystal Biotech's Accounts Payables registered a high of $59.0 million during Q4 2024, and its lowest value of $6.7 million during Q1 2021.
  • Moreover, its 5-year median value for Accounts Payables was $27.3 million (2025), whereas its average is $29.5 million.
  • As far as peak fluctuations go, Krystal Biotech's Accounts Payables surged by 66393.57% in 2022, and later plummeted by 4211.78% in 2023.
  • Over the past 5 years, Krystal Biotech's Accounts Payables (Quarter) stood at $16.3 million in 2021, then surged by 43.0% to $23.3 million in 2022, then dropped by 7.7% to $21.5 million in 2023, then soared by 174.23% to $59.0 million in 2024, then crashed by 32.61% to $39.8 million in 2025.
  • Its Accounts Payables stands at $39.8 million for Q4 2025, versus $31.7 million for Q3 2025 and $26.5 million for Q2 2025.